<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1180">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04703205</url>
  </required_header>
  <id_info>
    <org_study_id>CORVETTE-01</org_study_id>
    <nct_id>NCT04703205</nct_id>
  </id_info>
  <brief_title>Study in COvid-19 Patients With iveRmectin (CORVETTE-01)</brief_title>
  <official_title>A Placebo-controlled, Randomized, Double-blind Study in COvid-19 Patients With iveRmectin; An inVEstigator iniTiaTEd Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kitasato University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kitasato University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of mild COVID-19 is basically performed at an outpatient clinic, then when the&#xD;
      symptom and clinical findings exacerbate to a moderate level, patients are admitted. There is&#xD;
      no standard treatment for mild cases. This study will investigate whether ivermectin&#xD;
      administration suppresses the replication of SARS-CoV-2 in mild to moderate COVID-19 by&#xD;
      investigating the negative rate of SARS-CoV-2 PCR by a randomized controlled trial. Subjects&#xD;
      are assigned to two groups, the placebo group, and the ivermectin group. The target number of&#xD;
      each treatment arm is 120, a total of 240 cases. A single oral administration of 200 ㎍/kg of&#xD;
      ivermectin or an ivermectin-free placebo will be administered on an empty stomach. Time to&#xD;
      negativization of SARS-CoV-2 PCR as the primary endpoint with additional efficacy and safety&#xD;
      of the process will be investigated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>COVID-19 PCR test (SARS-CoV-2 nucleic acid detection) Period until the COVID-19 PCR test (SARS-CoV-2 nucleic acid detection) becomes negative</measure>
    <time_frame>15days</time_frame>
    <description>Period until the COVID-19 PCR test (SARS-CoV-2 nucleic acid detection) becomes negative</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>ivermectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivermectin group: Ivermectin approximately 200 μg/kg administered as a single oral dose on Day 1 (fasting state) subjects take the study drug (3 mg tablet of ivermectin) at the dose of the study drug taken once per body weight of the subject.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group: Placebo without ivermectin as an ingredient, single oral administration on Day 1 (fasting state) the control drug (ivermectin placebo tablet) at the dose of the study drug taken once per body weight of the subject.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin 3 MG</intervention_name>
    <description>Ivermectin approximately 200 μg/kg administered as a single oral dose on Day 1 (fasting state)</description>
    <arm_group_label>ivermectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo group: Placebo without ivermectin as an ingredient, single oral administration on Day 1 (fasting state)</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A person who has been diagnosed with COVID-19 (including asymptomatic) by the COVID-19&#xD;
             PCR test (SARS-CoV-2 nucleic acid detection) within 3 days before the qualification&#xD;
             test.&#xD;
&#xD;
          2. A person with oxygen saturation (SpO2) in the room air of 95% or more.&#xD;
&#xD;
          3. A person who are 20 years or older at the time of obtaining consent.&#xD;
&#xD;
          4. A person who weigh 40 kg or more at the time of qualification test.&#xD;
&#xD;
          5. A person who understands the content of this clinical trial and can obtain written&#xD;
             consent to participate in the clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A woman who is in lactation period or who may be pregnant, or those who do not agree&#xD;
             to prevent pregnancy by medically appropriate means for up to 7 days after study drug&#xD;
             administration.&#xD;
&#xD;
             Medically appropriate contraception means that using a combination of two or more of&#xD;
             the following: not having sexual intercourse, taking surgical sterilization such as&#xD;
             vasectomy or intrauterine device, taking oral contraceptive, using condom.&#xD;
&#xD;
          2. A person who has severe liver damage (AST or ALT at the time of qualification test is&#xD;
             more than 3 times the upper limit of institutional standard and total bilirubin is&#xD;
             more than twice the upper limit of institutional standard value), renal disorder (eGFR&#xD;
             of eligibility test value 30 mL/min/1.73m2 or less).&#xD;
&#xD;
          3. A person with hypersensitivity to ivermectin.&#xD;
&#xD;
          4. A person with a history of severe drug allergies such as Stevens-Johnson syndrome,&#xD;
             toxic epidermal necrolysis.&#xD;
&#xD;
          5. A person who has received the prohibited medication within the past month (within the&#xD;
             past 6 months for biologics), or those who need to use the prohibited medication&#xD;
             during the clinical trial period.&#xD;
&#xD;
          6. A person who are currently participating in other clinical trials or who have&#xD;
             participated in other clinical trials within 30 days before obtaining consent.&#xD;
&#xD;
          7. In addition, a person who is determined to be unsuitable as a subject of this clinical&#xD;
             trial by the principal investigator.&quot;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kunihiro K.Y Yamaoka, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kitasato University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kitasato University</last_name>
    <phone>+81357916398</phone>
    <email>ivm-iit@insti.kitasato-u.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kunihiro Yamaoka, Ph.D</last_name>
    <phone>+81427788111</phone>
    <email>yamaoka@med.kitasato-u.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kitasato University</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>COVID-19</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kitasato K University</last_name>
      <phone>+81357916398</phone>
      <email>ivm-iit@insti.kitasato-u.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Miwa M Nonaka</last_name>
      <phone>+81357916398</phone>
      <email>ivm-iit@insti.kitasato-u.ac.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Kunihiro K Yamaoka, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Nicolas P, Maia MF, Bassat Q, Kobylinski KC, Monteiro W, Rabinovich NR, Menéndez C, Bardají A, Chaccour C. Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis. Lancet Glob Health. 2020 Jan;8(1):e92-e100. doi: 10.1016/S2214-109X(19)30453-X.</citation>
    <PMID>31839144</PMID>
  </reference>
  <reference>
    <citation>Lv C, Liu W, Wang B, Dang R, Qiu L, Ren J, Yan C, Yang Z, Wang X. Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo. Antiviral Res. 2018 Nov;159:55-62. doi: 10.1016/j.antiviral.2018.09.010. Epub 2018 Sep 26.</citation>
    <PMID>30266338</PMID>
  </reference>
  <reference>
    <citation>Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.</citation>
    <PMID>32251768</PMID>
  </reference>
  <reference>
    <citation>Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. Chest. 2021 Jan;159(1):85-92. doi: 10.1016/j.chest.2020.10.009. Epub 2020 Oct 13.</citation>
    <PMID>33065103</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kitasato University</investigator_affiliation>
    <investigator_full_name>KUNIHIRO YAMAOKA</investigator_full_name>
    <investigator_title>KitasatoUniversity SchoolofMedicine Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

